We hypothesize that extending the paradigm of negative hyperselection in stage III CC patients enrolled in the PETACC-8 clinical trial beyond RAS/BRAF by means of a simplified PRESSING panel, in addition to MSI status and primary tumor location selection, may identify a subgroup deriving greater benefit from anti-EGFR agents also in the adjuvant setting. This evidence concerns the gene BRAF and neoplasm.